Merck Q3 PAT seen down 7.8% to Rs 16.5 cr: Centrum

Net Sales are expected to increase by 5 percent Q-o-Q (up 5.7 percent Y-o-Y) to Rs 270.5 crore, according to Centrum.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Earnings » Brokerage Results Estimates

Oct 19, 2016, 03.46 PM | Source: Moneycontrol.com

Merck Q3 PAT seen down 7.8% to Rs 16.5 cr: Centrum

Net Sales are expected to increase by 5 percent Q-o-Q (up 5.7 percent Y-o-Y) to Rs 270.5 crore, according to Centrum.

Like this story, share it with millions of investors on M3

Merck Q3 PAT seen down 7.8% to Rs 16.5 cr: Centrum

Net Sales are expected to increase by 5 percent Q-o-Q (up 5.7 percent Y-o-Y) to Rs 270.5 crore, according to Centrum.

Post Your Comments

Share Cancel

Centrum Broking (more)

, Centrum Broking |

Centrum has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Merck  to report net profit at Rs 16.5 crore, down 7.8 percent quarter-on-quarter.

Net Sales are expected to increase by 5 percent Q-o-Q (up 5.7 percent Y-o-Y) to Rs 270.5 crore, according to Centrum.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 3.6 percent Q-o-Q (up 44 percent Y-o-Y) to Rs 27.5 crore.

Centrum's report on Merck

For Q3CY16, we expect Merck to report revenue growth of 6% YoY and 5% QoQ to Rs2.71bn. Pharma sales (78% of revenues) are expected to grow by 17% YoY to Rs2.10bn. Chemical business (22% of revenues) is likely to decline by 24% YoY to Rs605mn as the company has discontinued selling vitamin E API.

The company is reducing its dependence on the low-margin chemicals business and concentrating on the high-margin pharma business. We expect the company’s flagship brands Neurobion Forte, Polybion and Nasivion to drive future growth.

The net profit is set to grow by 32% YoY to Rs165mn from Rs125mn due to margin improvement.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Tags  Merck Centrum
Buy, Hold, Sell ? Hear it first on M3
Merck Q3 PAT seen down 7.8% to Rs 16.5 cr: Centrum

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login